BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 27022050)

  • 21. Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
    Michos ED; Martin SS; Blumenthal RS
    Circulation; 2015 Sep; 132(13):1218-20. PubMed ID: 26330413
    [No Abstract]   [Full Text] [Related]  

  • 22. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ezetimibe plus simvastatin cardiovascular outcomes study program.
    Padial LR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):17-25. PubMed ID: 18095904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White J; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2016 Mar; 133(13):e463. PubMed ID: 27022050
    [No Abstract]   [Full Text] [Related]  

  • 25. IMPROVE-IT: what have we learned?
    Banach M; Nikolic D; Rizzo M; Toth PP
    Curr Opin Cardiol; 2016 Jul; 31(4):426-33. PubMed ID: 27218683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
    Serban MC; Banach M; Mikhailidis DP
    Expert Opin Pharmacother; 2016; 17(3):369-80. PubMed ID: 26559810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
    Kastelein JJ; Sankatsing RR
    Int J Clin Pract; 2005 Dec; 59(12):1464-71. PubMed ID: 16351680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The effect of a simvastatin and ezetimib combination on blood lipids and cardiovascular events in diabetic patients (comments on the subanalysis results within the IMPROVE-IT study)].
    Soška V
    Vnitr Lek; 2015 Nov; 61(11):965-9. PubMed ID: 26652785
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.